Juan A Marin-Jimenez
Overview
Explore the profile of Juan A Marin-Jimenez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rullan A, Marin-Jimenez J, Lozano A, Bermejo O, Arribas L, Ruiz N, et al.
Clin Transl Oncol
. 2024 May;
26(12):3003-3012.
PMID: 38782865
Purpose: Radiotherapy (RT) with concomitant cisplatin (CRT) or cetuximab (ERT) are accepted treatment options for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Long-term adverse events (AEs)...
2.
Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread
Gendrau-Sanclemente N, Figueras A, Gracova K, Lahiguera A, Alsina-Sanchis E, Marin-Jimenez J, et al.
Mol Oncol
. 2023 Nov;
18(1):136-155.
PMID: 38010623
High-grade serous ovarian cancer (HGSOC) is the deadliest gynecological malignancy. The most common form of metastatic spread of HGSOC is transcoelomic dissemination. In this process, detached cells from the primary...
3.
Lanis J, Lewis M, Strassburger H, Larsen K, Bagby S, Dominguez A, et al.
J Vis Exp
. 2023 Jan;
190.
PMID: 36591990
Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer...
4.
Lang J, Leal A, Marin-Jimenez J, Hartman S, Shulman J, Navarro N, et al.
Front Oncol
. 2022 Nov;
12:877635.
PMID: 36419897
Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC...
5.
Marin-Jimenez J, Oliva M, Peinado Martin P, Cabezas-Camarero S, Plana Serrahima M, Vazquez Masedo G, et al.
Front Oncol
. 2022 Aug;
12:953020.
PMID: 35936723
Objectives: Induction chemotherapy (ICT) followed by definitive treatment is an accepted non-surgical approach for locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, ICT remains a challenge for cisplatin-unfit...
6.
Marin-Jimenez J, Garcia-Mulero S, Matias-Guiu X, Piulats J
Clin Cancer Res
. 2022 Jul;
28(22):4849-4860.
PMID: 35789264
Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is not an exception. Approved treatment options are pembrolizumab or dostarlimab for mismatch repair...
7.
Marin-Jimenez J, Capasso A, Lewis M, Bagby S, Hartman S, Shulman J, et al.
Front Immunol
. 2021 Apr;
12:607282.
PMID: 33854497
Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500...
8.
Linares J, Marin-Jimenez J, Badia-Ramentol J, Calon A
Front Cell Dev Biol
. 2021 Feb;
8:621070.
PMID: 33553157
Multiple lines of evidence are indicating that cancer development and malignant progression are not exclusively epithelial cancer cell-autonomous processes but may also depend on crosstalk with the surrounding tumor microenvironment...